Mga Batayang Estadistika
| LEI | 35ZN6X1ANPH25YN32Y17 |
| CIK | 933974 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Azenta, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lawrence Lin, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| August 6, 2025 |
Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John Marotta, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 00 |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| August 5, 2025 |
Exhibit 99.1 Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance BURLINGTON, Mass., August 5, 2025 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, followin |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| May 30, 2025 |
Conflict Minerals Report for the year ended December 31, 2024 Exhibit 1.01 Introduction Azenta, Inc., also referred to as “Azenta”, “we”, “our”, and “us” is a leading provider of life sciences solutions worldwide. Azenta provides a full suite of reliable cold chain sample management solutions and multiomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AZENTA, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0‑25434 04‑3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 200 Summit Drive, 6th Floor, Burlington, MA 01803 (Address of Principal Executive Offices) ( |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| May 16, 2025 |
Severance Agreement and Release, dated May 15, 2025, between Azenta, Inc. and Jason W. Joseph. Exhibit 10.1 May 14, 2025 VIA EMAIL DELIVERY Jason W. Joseph Re: Transition and Separation Agreement and Release Dear Jason: This Transition and Separation Agreement and Release (the “Agreement”) summarizes the terms of your employment transition and separation from Azenta, Inc. (the “Company”) and is entered into as of May 15, 2025. 1. Transition. Effective on May 15, 2025 (the “Transition Date”) |
|
| May 9, 2025 |
Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lawrence Lin, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| May 9, 2025 |
Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John Marotta, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 0 |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| May 7, 2025 |
Exhibit 99.1 Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025 BURLINGTON, Mass., May 7, 2025 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company’s announcement in the first |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| April 9, 2025 |
Severance Agreement and Release, dated April 9, 2025, between Azenta, Inc. and David Wang Exhibit 10.1 EXHIBIT A THIS IS AN IMPORTANT LEGAL DOCUMENT. PLEASE CONFER WITH A LAWYER OR OTHER TRUSTED ADVISOR BEFORE SIGNING THIS DOCUMENT. April 9, 2025 VIA EMAIL DELIVERY David Wang Re: Separation Agreement and Release Dear David: This letter summarizes the terms of your separation from employment with Azenta, Inc. (the “Company”). The purpose of this Agreement is to establish an amicable arr |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Numbe |
|
| February 10, 2025 |
Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John Marotta, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| February 10, 2025 |
Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lawrence Lin, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 30, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 5, 2025 |
Exhibit 99.1 Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024 BURLINGTON, Mass., February 5, 2025 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2024. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company’s announcement in t |
|
| January 30, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 30, 2025 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| January 30, 2025 |
AZENTA, INC. Revised Financial Information Exhibit 99.1 AZENTA, INC. Revised Financial Information As previously disclosed on November 12, 2024, Azenta, Inc. (the “Company”) announced that it is pursuing a sale of its B Medical Systems segment, a manufacturer and global distributor of medical refrigeration devices based in Luxembourg. This strategic action is intended to simplify the Company’s portfolio and allow management to focus on dri |
|
| December 17, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidenti |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the |
|
| November 27, 2024 |
EXHIBIT 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John Marotta, certify that: 1. I have reviewed this annual report on Form 10-K of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such s |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-25434 |
|
| November 27, 2024 |
EXHIBIT 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Herman Cueto, certify that: 1. I have reviewed this annual report on Form 10-K of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such s |
|
| November 27, 2024 |
Exhibit 4.02 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Azenta, Inc. (referred to herein as “we”, “our”, “us” or “the Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following description of our capital stock summarizes the material te |
|
| November 27, 2024 |
Consent of PricewaterhouseCoopers LLP Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-252725, 333-202005, 333-216312, 333-221826 and 333-123242) of Azenta, Inc. of our report dated November 26, 2024 relating to the financial statements and the effectiveness of internal control over financial reporting, which |
|
| November 27, 2024 |
Exhibit 97 AZENTA, INC CLAWBACK POLICY I. Introduction The Board of Directors (the “Board”) of Azenta, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this poli |
|
| November 27, 2024 |
Azenta, Inc. Insider Trading and Confidentiality of Insider Information Policy Exhibit 19 Insider Trading and Confidentiality of Insider Information (effective as of February 1, 2022) Purpose: To define the Company’s rules on insider trading, to establish guidelines on the confidentiality of insider information, to prevent violations of insider trading laws by Company personnel, and to avoid even the appearance of improper conduct in this regard by Company personnel. |
|
| November 27, 2024 |
EXHIBIT 21.01 AZENTA, INC. SUBSIDIARIES OF THE REGISTRANT Legal Entity Jurisdiction Azenta Beijing Technologies Limited China Azenta (Guangzhou) Life Science Co., Ltd. China Azenta Germany GmbH Germany Azenta Japan Corp. Japan Azenta Life Sciences Canada, Inc. Canada Azenta Luxembourg SARL Luxembourg Azenta (Nanjing) Life Science Technologies Co., Ltd. China Azenta Switzerland AG Switzerland Azent |
|
| November 13, 2024 |
AZTA / Azenta, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0090889-3sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 3)* AZENTA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 114340102 (CUSIP Number) September 30, 2024 (Da |
|
| November 12, 2024 |
Exhibit 99.1 Azenta Reports Fourth Quarter and Full Year Fiscal 2024 Results; Announces the Plan to Sell B Medical Systems and Appoints Lawrence Y. Lin as CFO ● FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and Multiomics ● FY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basi |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| November 12, 2024 |
Offer Letter, dated November 11, 2024, between Azenta, Inc. and Lawrence Lin Exhibit 10.2 November 8, 2024 Mr. Lawrence Lin Dear Lawrence: On behalf of Azenta, it is my pleasure to offer you the position of Executive Vice President and Chief Financial Officer. It is intended that you would join Azenta as Executive Vice President, Finance, and you would assume the role of Chief Financial Officer after the Company’s Annual Report on Form 10-K for the fiscal year ended Septem |
|
| November 12, 2024 |
Exhibit 10.1 THIS IS AN IMPORTANT LEGAL DOCUMENT. PLEASE CONFER WITH A LAWYER OR OTHER TRUSTED ADVISOR BEFORE SIGNING THIS DOCUMENT. November 12, 2024 VIA EMAIL DELIVERY Herman Cueto Re: Transition and Severance Agreement and Release Dear Herman: This letter summarizes the terms of your separation from employment with Azenta, Inc. (the “Company”). The purpose of this agreement (“Agreement”) is to |
|
| November 4, 2024 |
Exhibit 99.1 Press Release Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Dir |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 4, 2024 |
Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”), dated as of November 1, 2024 (the “Effective Date”), is by and among Politan Capital Management LP, a Delaware limited partnership, Politan Capital Management GP LLC, a Delaware limited liability company, Politan Capital NY LLC, a New York limited liability company, and Politan Capital Partners GP LLC, a Delaware lim |
|
| November 4, 2024 |
AZTA / Azenta, Inc. / Politan Capital Management LP - SC 13D/A Activist Investment SC 13D/A 1 tm2427378d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Azenta, Inc. (Name of Issuer) Common Stock, par value $0.01 per share |
|
| October 31, 2024 |
AZTA / Azenta, Inc. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Azenta Inc (Name of Issuer) Common Stock (Title of Class of Securities) 114340102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 4, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| September 4, 2024 |
Employment Agreement, dated September 3, 2024, by and between the Company and John Marotta. Exhibit 10.1 EXECUTION COPY EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made as of the date that this Agreement is fully executed between Azenta, Inc. (the “Company”) and John Marotta (“Executive”) (collectively, the Company and Executive, are the “Parties”). WHEREAS, the Company wishes to employ Executive and Executive wishes to be employed by the Company pursuant to the |
|
| September 4, 2024 |
Exhibit 99.1 AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., September 4, 2024 /PRNewswire/ - Azenta, Inc. (Nasdaq: AZTA) (“Azenta” or “the Company”), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following |
|
| August 6, 2024 |
Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Herman Cueto, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 00 |
|
| August 6, 2024 |
Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh |
|
| August 6, 2024 |
Exhibit 99.1 Azenta Reports Third Quarter Results for Fiscal 2024, Ended June 30, 2024 BURLINGTON, Mass., August 6, 2024 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2024. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operatio |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AZENTA, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 200 Summit Drive, 6th Floor, Burlington, MA 01803 (Address of Principal Executive Offices) ( |
|
| May 30, 2024 |
Conflict Minerals Report for the year ended December 31, 2023 Exhibit 1.01 Introduction Azenta, Inc., also referred to as “Azenta”, “we”, “our”, and “us” is a leading provider of life sciences solutions worldwide. Azenta provides a full suite of reliable cold chain sample management solutions and multiomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and |
|
| May 9, 2024 |
Exhibit 99.1 Azenta Announces CEO Succession Plan CEO Dr. Stephen Schwartz to Retire; Search Underway to Identify Successor BURLINGTON, Mass., May 8, 2024 /PRNewswire/ - Azenta, Inc. (Nasdaq: AZTA) today announced a CEO succession plan, under which CEO and Board Director Dr. Stephen Schwartz will be retiring from Azenta after more than 14 years of service. Dr. Schwartz will continue to serve as CE |
|
| May 9, 2024 |
Transition Agreement, dated May 8, 2024, between Azenta, Inc. and Stephen S. Schwartz. EXHIBIT 10.1 TRANSITION AGREEMENT This Transition Agreement (this “Agreement”) dated May 8, 2024 is between Azenta, Inc., a Delaware corporation (“Company”) and Stephen S. Schwartz (“Employee”). WHEREAS, Employee currently serves as President and Chief Executive Officer of the Company (the “CEO”); WHEREAS, Employee has announced Employee’s intention to retire as the Company’s CEO; WHEREAS, the Com |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 0 |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| May 8, 2024 |
Exhibit 99.1 Azenta Reports Second Quarter Results for Fiscal 2024, Ended March 31, 2024 BURLINGTON, Mass., May 8, 2024 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2024. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2024 2023 2023 Prior Qtr Prior Yr. Revenue from Continuing Op |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| March 14, 2024 |
Exhibit 99.1 © 2024 Azenta, Inc. All rights reserved Transforming our Platform for Sustained Profitable Growth Investor Day March 14, 2024 Azenta Life Sciences | Proprietary and confidential. Welcome Sara Silverman Head of Investor Relations 2 © 2024 Azenta, Inc. All rights reserved Safe Harbor Statement 3 “Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995; cer |
|
| March 14, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| February 13, 2024 |
BRKS / Brooks Automation, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0391-azentainc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 15)* Name of issuer: Azenta Inc Title of Class of Securities: Common Stock CUSIP Number: 114340102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule purs |
|
| February 13, 2024 |
BRKS / Brooks Automation, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0086862-10sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 2)* AZENTA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 114340102 (CUSIP Number) December 31, 2023 (Da |
|
| February 8, 2024 |
Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh |
|
| February 8, 2024 |
Separation Agreement dated January 2, 2024 between the Company and David C. Gray. Exhibit 10.2 THIS IS AN IMPORTANT LEGAL DOCUMENT. PLEASE CONFER WITH A LAWYER OR OTHER TRUSTED ADVISOR BEFORE SIGNING THIS DOCUMENT. December 11, 2023 VIA EMAIL DELIVERY David C. Gray Re: Severance Agreement and Release Dear Dave: This letter summarizes the terms of your separation from employment with Azenta, Inc. (the “Company”). The purpose of this Agreement is to establish an amicable arrangem |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Numbe |
|
| February 8, 2024 |
Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Herman Cueto, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which suc |
|
| February 8, 2024 |
Transition Letter Agreement dated December 4, 2023 between the Company and Lindon G. Robertson. Exhibit 10.1 December 4, 2023 VIA EMAIL Lindon G. Robertson Re: Transition Letter Agreement Dear Lindon: This Transition Letter Agreement confirms our recent discussions regarding your retirement plans from Azenta Life Sciences (“Azenta”). We have agreed that your last date of employment will be on February 16, 2024. Effective immediately and until that date, your role will be modified to Advisor |
|
| February 7, 2024 |
Exhibit 99.1 Azenta Reports First Quarter Results for Fiscal 2024, Ended December 31, 2023 BURLINGTON, Mass., February 7, 2024 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2023. Quarter Ended Dollars in millions, except per share data December 31, September 30, December 31, Change 2023 2023 2022 Prior Qtr Prior Yr. Revenue fr |
|
| February 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 7, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 1, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 30, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| January 31, 2024 |
Exhibit 99.1 Notes on Non-GAAP Financial Measures Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, purchase price accounting adjustments, tariff adjustments, restructu |
|
| January 31, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2024 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6 |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6 |
|
| December 15, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permi |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6 |
|
| November 21, 2023 |
EXHIBIT 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Herman Cueto, certify that: 1. I have reviewed this annual report on Form 10-K of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such s |
|
| November 21, 2023 |
Exhibit 4.02 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of September 30, 2023, Azenta, Inc. (referred to herein as “we”, “our”, “us” or “the Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. The following description of our capital stock |
|
| November 21, 2023 |
EXHIBIT 21.01 AZENTA, INC. SUBSIDIARIES OF THE REGISTRANT Legal Entity Jurisdiction Abeyatech LLC USA Azenta Beijing Technologies Limited China Azenta (Guangzhou) Life Science Co., Ltd. China Azenta Germany GmbH Germany Azenta Japan Corp. Japan Azenta Life Sciences Canada, Inc. Canada Azenta Luxembourg SARL Luxembourg Azenta (Nanjing) Life Science Technologies Co., Ltd. China Azenta Switzerland AG |
|
| November 21, 2023 |
EXHIBIT 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this annual report on Form 10-K of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-25434 |
|
| November 21, 2023 |
Offer Letter, dated September 21, 2023, between the Company and Herman Cueto. Exhibit 10.06 September 21, 2023 Mr. Herman Cueto 855 Boulevard Westfield, NJ 07090 Dear Herman: I am very happy to extend an offer to become part of Azenta (the “Company”) and our executive team. Our numerous discussions have only solidified my strong impressions that you will provide the strategic leadership necessary to continue Azenta’s growth while enabling our customers to bring impactful br |
|
| November 21, 2023 |
Consent of PricewaterhouseCoopers LLP Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-252725, 333-202005, 333-216312, 333-221826 and 333-123242) of Azenta, Inc. of our report dated November 20, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which |
|
| November 15, 2023 |
BRKS / Brooks Automation, Inc. / Politan Capital Management LP - SC 13D/A Activist Investment SC 13D/A 1 tm2330790d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Azenta, Inc. (Name of Issuer) Common Stock, par value $0.01 per share |
|
| November 13, 2023 |
Azenta Announces Actions to Support Ongoing Strategic and Governance Transformation Exhibit 99.2 Azenta Announces Actions to Support Ongoing Strategic and Governance Transformation ● Nominates Didier Hirsch and Martin Madaus for election to the Board of Directors ● Upon the election of Messrs. Hirsch and Madaus, seven of the Board of Directors’ ten members will have been added since 2018 ● Separately, Azenta today announced strong 2023 fourth quarter and full year fiscal 2023 ear |
|
| November 13, 2023 |
Exhibit 99.1 Azenta Reports Fourth Quarter and Full Year Fiscal 2023 Results, Ended September 30, 2023 ● Q4’23 reported revenue growth of 25% year over year and 2% on an organic basis ● FY’23 reported revenue growth of 20% and down 1% on an organic basis ● Q4’23 generated positive free cash flow for the second consecutive quarter ● Fiscal 2024 organic revenue growth expected to be 5-8% ● Committin |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 13, 2023 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| November 1, 2023 |
EX-99.3 2 tm2329437d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 TRADING DATA The following table sets forth all transactions in the Common Stock of the Issuer effected by the Politan Funds since the filing of the Initial 13D. Except as otherwise noted below, all such transactions were purchases or sales of shares of Common Stock effected in the open market, and the table excludes commissions paid in per |
|
| November 1, 2023 |
BRKS / Brooks Automation, Inc. / Politan Capital Management LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Azenta, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 114340102 |
|
| September 26, 2023 |
Exhibit 99.1 Azenta Announces CFO Transition Industry Veteran Herman Cueto Named CFO Azenta CFO Lindon Robertson to Retire Company Reaffirms Guidance for Fourth Quarter Fiscal 2023 BURLINGTON, Mass., Sept. 26, 2023 /PRNewswire/ – Azenta, Inc. (Nasdaq: AZTA) today announced that Herman Cueto will join Azenta as Executive Vice President and Chief Financial Officer, effective October 16. Mr. Cueto, w |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 22, 2023 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| September 14, 2023 |
Exhibit 99.2 TRADING DATA The following table sets forth all transactions in the Common Stock of the Issuer effected in the last sixty days by the Politan Funds. Except as otherwise noted below, all such transactions were purchases or sales of shares of Common Stock effected in the open market, and the table excludes commissions paid in per share prices. Trade Date Expiration Date Buy/Sell No. of |
|
| September 14, 2023 |
BRKS / Brooks Automation, Inc. / Politan Capital Management LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 Azenta, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 114340102 (CUSIP Number) Quen |
|
| September 14, 2023 |
EX-99.1 2 tm2326163d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing, along with all other such undersigned, on behalf of the Reporting Persons (as defined in the joint filing), of a statement on Schedule 13D (including amendments thereto) |
|
| August 9, 2023 |
AMENDED AND RESTATED BYLAWS OF AZENTA, INC. A DELAWARE CORPORATION Most recently amended as of August 7, 2023 TABLE OF CONTENTS Page ARTICLE I Stockholders1 Section 1.1 Annual Meeting1 Section 1.2 Special Meetings1 Section 1.3 Notice of Meeting1 Section 1.4 Quorum/Adjournments2 Section 1.5 Voting and Proxies2 Section 1.6 Action at Meeting2 Section 1.7 Action Without Meeting3 Section 1.8 Vo |
|
| August 9, 2023 |
Separation Agreement dated as of August 4, 2023 between the Company and Vandana Sriram THIS IS AN IMPORTANT LEGAL DOCUMENT. PLEASE CONFER WITH A LAWYER OR OTHER TRUSTED ADVISOR BEFORE SIGNING THIS DOCUMENT. August 2, 2023 VIA HAND DELIVERY Vandana Sriram 51 Robinson Road Lexington, MA 02420 Re: Separation Agreement and Release Dear Vandana: This letter summarizes the terms of your separation from employment with Azenta, Inc. (the “Company”). The purpose of this Agreement is to estab |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 00 |
|
| August 8, 2023 |
Exhibit 99.1 Azenta Reports Results of Third Quarter of Fiscal 2023, Ended June 30, 2023 BURLINGTON, Mass., August 8, 2023 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2023. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2023 2023 2022 Prior Qtr Prior Yr. Revenue from Continuing Operat |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2023 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AZENTA, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 200 Summit Drive, 6th Floor, Burlington, MA 01803 (Address of Principal Executive Offices) ( |
|
| May 31, 2023 |
Conflict Minerals Report for the year ended December 31, 2022 Exhibit 1.01 Introduction Azenta, Inc., also referred to as “Azenta”, “we”, “our”, and “us” is a leading provider of life science solutions worldwide. Azenta provides a full suite of reliable cold chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and he |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 0 |
|
| May 9, 2023 |
Exhibit 99.1 Azenta Reports Results of Second Quarter of Fiscal 2023 and Announces Business Realignment BURLINGTON, Mass., May 9, 2023 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2023. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2023 2022 2022 Prior Qtr Prior Yr. Revenue fro |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| February 14, 2023 |
SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* AZENTA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 114340102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Azenta, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 114340102 (CUSIP Number) December 31, 2022 (Date of Event Which R |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Numbe |
|
| February 8, 2023 |
Exhibit 99.1 Azenta Reports First Quarter Results For Fiscal 2023, Ended December 31, 2022 ● Reported Q1’23 Revenue of $178 Million and Growth of 28% Year-Over-Year ● Delivered Organic Growth Excluding COVID of 7% ● Reducing Cost Structure to Deliver Two Points of Margin Enhancement in 2nd Half FY23 BURLINGTON, Mass., February 8, 2023 (PR Newswire) - Azenta, Inc. (Nasdaq: AZTA) today reported fina |
|
| February 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2023 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 8, 2023 |
Exhibit 99.2 1 Azenta Life Sciences | Proprietary and confidential. Conference Call Fir s t Q u a r t e r Fis c al 2 0 2 3 Fin a n cial R e s ults February 8, 2023 2 Azenta Life Sciences | Proprietary and confidential. Safe Harbor Statement Regulation G This presentation contains certain non-GAAP measures which are provided to assist in an understanding of the Azenta business and its operational p |
|
| February 2, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2023 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| January 10, 2023 |
BRKS / Brooks Automation, Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0003-azentainc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 14)* Name of issuer: Azenta Inc. Title of Class of Securities: Common Stock CUSIP Number: 114340102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pur |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) ? Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? ? ? ? Preliminary Proxy Statement ? ? ? ? ? Confidential, For Use of the Commission Only (as p |
|
| December 21, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) ? Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? ? ? ? Preliminary Proxy Statement ? ? ? ? ? Confidential, For Use of the Com |
|
| December 15, 2022 |
Table of Contents Exhibit 99.1 B Medical Systems Holding S.A. (in liquidation) Consolidated annual accounts for the years ended 31 December 2021 and 2020 ? ? ? Op der Hei, 17 L-9809 Hosingen Luxembourg R.C.S. Luxembourg : B 94593 Share capital: EUR 31,000 ? ? ? Table of Contents ? ? ? ? ? Contents Page(s) ? ? ? Report of the Independent Auditors ? 1 ? ? ? Consolidated balance sheet at 31 December |
|
| December 15, 2022 |
Table of Contents Exhibit 99.2 ? ? B Medical Systems Holding S.A. (in liquidation) Consolidated interim accounts for the six months ended 30 June 2022 ? ? ? ? ? ? ? ? ? ? ? ? Op der Hei, 17 L-9809 Hosingen Luxembourg R.C.S. Luxembourg : B 94593 Share capital: EUR 31,000 Table of Contents Exhibit 99.2 ? ? Contents Page(s) ? ? Consolidated balance sheet as at 30 June 2022 (unaudited) 1 ? ? Consolida |
|
| December 15, 2022 |
Table of Contents Exhibit 99.3 ? ? Table of Contents ? ? ? ? Unaudited Pro Forma Condensed Combined Financial Information 1 Unaudited Pro Forma Condensed Combined Balance Sheet as of September 30, 2022 3 Unaudited Pro Forma Condensed Combined Income Statement for the year ended September 30, 2022 5 Note 1. Description of the Transaction 6 Note 2. Basis of Pro Forma Presentation 6 Note 3. Significa |
|
| December 15, 2022 |
Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K/A (Amendment No. 1) ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): October 3, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorpora |
|
| November 25, 2022 |
EXHIBIT 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this annual report on Form 10-K of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which |
|
| November 25, 2022 |
EXHIBIT 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lindon G. Robertson, certify that: 1. I have reviewed this annual report on Form 10-K of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which |
|
| November 25, 2022 |
Consent of PricewaterhouseCoopers LLP Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-252725, 333-202005, 333-216312, 333-221826, 333-123242 and 333-142873) of Azenta, Inc. of our report dated November 25, 2022, relating to the consolidated financial statements and the effectiveness of internal control over f |
|
| November 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-25434 |
|
| November 25, 2022 |
EXHIBIT 21.01 AZENTA, INC. SUBSIDIARIES OF THE REGISTRANT Legal Entity Jurisdiction Abeyatech LLC USA Azenta Beijing Technologies Limited China Azenta (Guangzhou) Life Science Co., Ltd. China Azenta Germany GmbH Germany Azenta Japan Corp. Japan Azenta Life Sciences Canada, Inc. Canada Azenta Luxembourg SARL Luxembourg Azenta (Nanjing) Life Science Technologies Co., Ltd. China Azenta Switzerland AG |
|
| November 23, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): November 23, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 23, 2022 |
? Exhibit 10.1 ? ? To: Azenta, Inc. 15 Elizabeth Drive Chelmsford, Massachusetts 01824 ? ? From: JPMorgan Chase Bank, National Association New York Branch 383 Madison Avenue New York, NY 10179 ? ? Re: Accelerated Stock Repurchase Transaction(s) ? ? Date: November 23, 2022 ? ? ? This master confirmation (this ?Master Confirmation?), dated as of November 23, 2022, is intended to set forth certain te |
|
| November 23, 2022 |
Azenta Announces $500 Million Accelerated Share Repurchase Agreement Exhibit 99.1 Azenta Announces $500 Million Accelerated Share Repurchase Agreement CHELMSFORD, Mass., November 23, 2022 (PR Newswire) ? Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered into an accelerated share repurchase agreement (?ASR?) with JP Morgan Chase Bank, N.A. (the ?Dealer?) to repurchase $500 million of the Company?s common stock. The ASR was entered into pursuant to the |
|
| November 14, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): November 11, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 14, 2022 |
Exhibit 99.1 ? Azenta Reports Fourth Quarter and Full Year Fiscal 2022 Results, Authorizes $1.5 Billion Share Repurchase Program ? ? Delivered on Expected Q4?22 Revenue of $138 million ? Strong Double-Digit Organic Growth Excluding COVID for Q4 and Full Fiscal Year ? Plan to Repurchase at Least $1 Billion of Common Stock Over the Coming Year, Including $500 Million Accelerated Share Repurchase Pro |
|
| October 17, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): October 12, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| October 7, 2022 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): October 3, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| October 7, 2022 |
? Exhibit 99.1 ? ? ? ? Azenta Announces Completion of B Medical Systems Acquisition ? CHELMSFORD, Mass., October 3, 2022 (PRNewswire) ? Azenta, Inc. (Nasdaq: AZTA) today announced that it has closed its previously announced acquisition of B Medical Systems S.? r.l and its subsidiaries (?B Medical?), a market leader in temperature-controlled storage and transportation solutions that enables the del |
|
| August 10, 2022 |
? Exhibit 99.1 ? Azenta Announces Agreement to Acquire B Medical Systems ? Enhances Azenta?s Leadership Position in Cold Chain Solutions and End-to-End Sample Management CHELMSFORD, Mass., August 8, 2022 (PRNewswire) ? Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered into a definitive agreement to acquire B Medical Systems S.? r.l and its subsidiaries (?B Medical?), a market leader |
|
| August 10, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): August 8, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 10, 2022 |
Exhibit 2.1 ? DATED 8 AUGUST 2022 ? ? Certain identified information has been omitted from this exhibit because it is not material and of the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. ? B MEDICAL SYSTEMS HOLDING S.A. ? - and - AZENTA LUXEMBOURG S.? R.L. ? - and - ? AZENTA, INC. ? ? SHARE PURCHASE AGREEMENT IN RESPECT OF ? B MEDIC |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): August 9, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 9, 2022 |
Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 9, 2022 |
Exhibit 99.1 Azenta Life Sciences Reports Results of Third Quarter of Fiscal 2022, Ended June 30, 2022 ? CHELMSFORD, Mass., August 9, 2022 (PR Newswire) - Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2022. ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? Quarter Ended ? ? ? ? ? ? ? Dollars in millions, except per share data ? June 30, ? March 31, ? Jun |
|
| August 9, 2022 |
Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lindon G. Robertson, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Azenta, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh |
|
| July 13, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): July 13, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 13, 2022 |
Exhibit 99.1 Azenta Reports Preliminary Results for Third Quarter of Fiscal 2022, Ended June 30, 2022 and Announces Earnings Conference Call and Webcast CHELMSFORD, Mass., July 13, 2022 (PRNewswire) ? Azenta, Inc. (Nasdaq: AZTA) today reported preliminary results for its third fiscal quarter ended June 30, 2022. The Company expects revenue of approximately $133 million, an increase of 3% compared |
|
| June 15, 2022 |
Azenta Announces Agreement to Acquire Barkey Holding GmbH Exhibit 99.1 ? Azenta Announces Agreement to Acquire Barkey Holding GmbH ? CHELMSFORD, Mass., June 8, 2022 (PRNewswire) ? Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered into a definitive agreement to acquire Barkey Holding GmbH and its subsidiaries (?Barkey?), a leading provider of controlled rate thawing devices to medical, biotech and pharma industries. Barkey is headquartered i |
|
| June 15, 2022 |
Exhibit 2.1 Execution Version ? ? AGREEMENT ON THE SALE AND TRANSFER OF SHARES (Vertrag ?ber den Kauf und die Abtretung von Gesch?ftsanteilen) ? between MR THOMAS BARKEY and SWISSFINITY I BETEILIGUNGS GMBH as Sellers and AZENTA GERMANY GMBH as Buyer ? and MR CHRISTIAN BARKEY ? STRICTLY PRIVATE AND CONFIDENTIAL ? [NOTARIAL FORM REQUIRED] ? ? Execution Version CONTENTS CLAUSE PAGE ? ? ? ? ? ? 1. Int |
|
| June 15, 2022 |
Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): June 7, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 8, 2022 |
Exhibit 2.1 Execution Version ? ? AGREEMENT ON THE SALE AND TRANSFER OF SHARES (Vertrag ?ber den Kauf und die Abtretung von Gesch?ftsanteilen) ? between MR THOMAS BARKEY and SWISSFINITY I BETEILIGUNGS GMBH as Sellers and AZENTA GERMANY GMBH as Buyer ? and MR CHRISTIAN BARKEY ? STRICTLY PRIVATE AND CONFIDENTIAL ? [NOTARIAL FORM REQUIRED] ? ? Execution Version CONTENTS CLAUSE PAGE ? ? ? ? ? ? 1. Int |
|
| June 8, 2022 |
Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): June 7, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 8, 2022 |
Press release issued on June 8, 2022 by Azenta, Inc. Exhibit 99.1 ? Azenta Announces Agreement to Acquire Barkey Holding GmbH ? CHELMSFORD, Mass., June 8, 2022 (PRNewswire) ? Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered into a definitive agreement to acquire Barkey Holding GmbH and its subsidiaries (?Barkey?), a leading provider of controlled rate thawing devices to medical, biotech and pharma industries. Barkey is headquartered i |
|
| May 26, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report AZENTA, INC. (Exact Name of Registrant as Specified in Charter) ? Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) ? (Commission File Number) ? (IRS Employer Identification No.) ? ? 15 Elizabeth Drive, Chelmsford, MA 01824 (Address of Principal Executive Offices |
|
| May 26, 2022 |
Conflict Minerals Report for the year ended December 31, 2021 ? Exhibit 1.01 Introduction Azenta Life Sciences, also referred to as ?Azenta?, ?we?, ?our?, and ?us? is a leading provider of life science solutions worldwide. Azenta provides a full suite of reliable cold chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, acade |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 11, 2022 |
? ? SEC FILE NUMBER 000-25434 ? CUSIP NUMBER 114340102 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 9, 2022 |
Exhibit 99.1 Azenta Life Sciences Reports Preliminary Results of Second Quarter of Fiscal 2022, Ended March 31, 2022 ? Robust customer demand bolstered by operational execution drives strong second quarter results ? CHELMSFORD, Mass., May 9, 2022 (PR Newswire) - Azenta, Inc. (Nasdaq: AZTA) today reported preliminary financial results for the second quarter ended March 31, 2022. ? ? Summary of Prel |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): May 9, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* AZENTA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 114340102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 10, 2022 |
SC 13G/A 1 tm225951d10sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Azenta, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 114340102 (CUSIP Number |
|
| February 9, 2022 |
BRKS / Brooks Automation, Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Azenta Inc. Title of Class of Securities: Common Stock CUSIP Number: 114340102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1 |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 8, 2022 |
Exhibit 99.1 Azenta Life Sciences Reports Results of First Quarter of Fiscal 2022, Ended December 31, 2021 Continued Double-Digit Growth, Healthy End Markets, and a Strong Balance Sheet CHELMSFORD, Mass., February 8, 2022 (PR Newswire) - Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fiscal quarter ended December 31, 2021. ? ? Summary of Results Results of continuing operatio |
|
| February 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): February 8, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 1, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 1, 2022 |
Exhibit 99.1 ? Azenta Life Sciences Completes Sale of Semiconductor Solutions Group Business to Thomas H. Lee Partners CHELMSFORD, Mass., February 1, 2022 (PRNewswire) ? Azenta, Inc. (Nasdaq: AZTA) today announced that it has completed the previously announced sale of the company?s Semiconductor Solutions Group business (or ?automation business?) to Thomas H. Lee Partners (?THL?) for $3.0 billion |
|
| February 1, 2022 |
Exhibit 2.1 ? FIRST AMENDMENT TO THE EQUITY INTEREST PURCHASE AGREEMENT This FIRST AMENDMENT TO THE EQUITY INTEREST PURCHASE AGREEMENT (this ?Amendment?), dated as of January 31, 2022, is entered into by and between Altar BidCo, Inc., a Delaware corporation (?Purchaser?), and Azenta, Inc. (f/k/a Brooks Automation, Inc.), a Delaware corporation (?Seller?). Capitalized terms used but not defined her |
|
| February 1, 2022 |
? Exhibit 10.1 STANDARD COMMERCIAL LEASE ARTICLE 1.00 BASIC LEASE TERMS 1.01Parties. This Standard Commercial Lease (this ?Lease?) is entered into as of this February 1, 2022 (the ?Effective Date?) by and between ALTAR BIDCO, INC., a Delaware corporation (?Landlord?), and AZENTA, INC. (f/k/a BROOKS AUTOMATION, INC.), a Delaware corporation (?Tenant?). 1.02Premises. In consideration of the rents, t |
|
| February 1, 2022 |
? Exhibit 10.2 STANDARD COMMERCIAL LEASE ARTICLE 1.00 BASIC LEASE TERMS 1.01Parties. This Standard Commercial Lease (this ?Lease?) is entered into as of this February 1, 2022 (the ?Effective Date?) by and between ALTAR BIDCO, INC., a Delaware corporation (?Landlord?), and AZENTA, INC. (f/k/a BROOKS AUTOMATION, INC.), a Delaware corporation (?Tenant?). ? 1.02Premises. In consideration of the rents, |
|
| January 28, 2022 |
Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 24, 2022 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) ? Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? ? ? ? Preliminary Proxy Statement ? ? ? ? ? Confidential, For Use of the Commission Only (as p |
|
| December 15, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permi |
|
| December 1, 2021 |
Exhibit 3.1 ? CERTIFICATE OF AMENDMENT ? TO ? CERTIFICATE OF INCORPORATION ? OF ? BROOKS AUTOMATION, INC. ? It is hereby certified that: ? 1.The name of the corporation (hereinafter called the ?Corporation?) is Brooks Automation, Inc. ? 2.The date of filing of the original Certificate of Incorporation of the Corporation with the Secretary of State of the State of Delaware was November 14, 1994. Th |
|
| December 1, 2021 |
Amended and Restated Bylaws of Azenta, Inc., effective as of December 1, 2021. Exhibit 3.2 ? ? ? ? ? ? ? ? ? ? ? ? AMENDED AND RESTATED BYLAWS OF AZENTA, INC. A DELAWARE CORPORATION ? ? ? Most recently amended as of ? December 1, 2021 ? ? ? TABLE OF CONTENTS ? Page ? ? ARTICLE I. Stockholders 1 ? ? Section 1.1. Annual Meeting 1 ? ? Section 1.2. Special Meetings 1 ? ? Section 1.3. Notice of Meeting 1 ? ? Section 1.4. Quorum 2 ? ? Section 1.5. Voting and Proxies 2 ? ? Section |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 1, 2021 Azenta, Inc. (Exact name of registrant as specified in its charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| December 1, 2021 |
Exhibit 99.1 Azenta, Inc. (Nasdaq: AZTA) Announces Completion of Corporate Name and Stock Ticker Symbol Change from Brooks Automation, Inc. (Nasdaq: BRKS) Effective at the open of market trading today, the Company will begin trading as Azenta, Inc. (Nasdaq: AZTA) CHELMSFORD, Mass., December 1, 2021 (PR Newswire) - Azenta, Inc. (Nasdaq: AZTA) (?Azenta? or the ?Company?) announced today that it has |
|
| November 24, 2021 |
Exhibit 10.17 [NAME] BROOKS AUTOMATION, INC. 2020 EQUITY INCENTIVE PLAN Stock Unit ? Award Notice This award notice sets forth the terms of the award (the ?Award?), described below, of restricted Stock Units (the ?RSUs?) under the Brooks Automation, Inc. 2020 Equity Incentive Plan (the ?Plan?) to the Participant identified below. The Award is subject to the terms of the Plan, which are incorporate |
|
| November 24, 2021 |
EXHIBIT 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this annual report on Form 10-K of Brooks Automation, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances |
|
| November 24, 2021 |
EXHIBIT 21.01 ? BROOKS AUTOMATION, INC. SUBSIDIARIES OF THE REGISTRANT ? ? ? Legal Entity Jurisdiction Abeyatech LLC USA Azenta Germany GmbH Germany Azenta Japan Corp. Japan Azenta Life Sciences Canada, Inc. Canada Azenta Luxembourg SARL Luxembourg Azenta Switzerland AG Switzerland Azenta UK Ltd UK Azenta US, Inc. USA BioSpeciman Corporation Canada Biostorage Technologies Asia Pacific Pte Ltd Sing |
|
| November 24, 2021 |
EXHIBIT 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lindon G. Robertson, certify that: 1. I have reviewed this annual report on Form 10-K of Brooks Automation, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 24, 2021 |
Consent of PricewaterhouseCoopers LLP Exhibit 23.01 ? ? CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-23313) and Form S-8 (Nos. 333-252725, 333-202005, 333-216312, 333-221826, 333-123242 and 333-142873) of Brooks Automation, Inc. of our report dated November 24, 2021, relating to the consolidated financial statements and |
|
| November 24, 2021 |
Exhibit 10.21 ? Non-Employee Directors ? [Year] Stock Grant/RSU Election Form ? Name (Last, First, Middle Initial) ? This form allows you to elect between shares of Brooks stock or Restricted Stock Units (?RSUs?) that may be awarded to you during calendar year [Year] under the Brooks Automation, Inc. 2020 Equity Incentive Plan (?Plan?) as compensation for your service as a member of the Board of D |
|
| November 24, 2021 |
Letter Agreement, dated October 4, 2021, between the Company and Amy Liao. Exhibit 10.08 ? ? ? Brooks Automation, Inc. 15 Elizabeth Drive Chelmsford, MA 01824 Tel (978) 262-2400 Fax (978) 262-2500 www.brooks.com October 4, 2021 Amy Liao Dear Amy: As a follow up to our discussion, the following terms surrounding your position will be effective as of October 11, 2021. We believe you can continue to provide significant value to our Company given our current business focus a |
|
| November 18, 2021 |
FinancialOverview–Driving Growth Lindon Robertson, EVP and Chief Financial Officer Exhibit 99.1 FinancialOverview?Driving Growth Lindon Robertson, EVP and Chief Financial Officer ? ? A G E N D A Financial Overview ? Driving Growth Strong performance track record Disciplined capital allocation Outlook: Compelling growth ahead 2 ? 2021 Brooks Automation, Inc. ? Proprietary Information ? ? The Growth Continues ? Building a Powerhouse in Life Sciences FY2019 FY2021 4% 17% Non-GAAP f |
|
| November 18, 2021 |
Exhibit 99.2 Brooks Automation Announces Planned Name and Stock Ticker Symbol Change ? Azenta, Inc. (Nasdaq: AZTA) Set to Begin Trading Effective December 1st CHELMSFORD, Mass., November 16, 2021 (PR Newswire) - Brooks Automation, Inc. (Nasdaq: BRKS) announced at its investor day earlier today that it is changing its name to Azenta, Inc. and will begin trading on Nasdaq under the ticker symbol AZT |
|
| November 18, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 10, 2021 |
Exhibit 99.1 Brooks Automation Reports Results of Fourth Quarter of Fiscal 2021, Ended September 30, 2021, and Announces Quarterly Cash Dividend ? Strong Double-Digit Growth Quarter Underscores Robust Demand Environment in Life Sciences ? CHELMSFORD, Mass., November 10, 2021 (PR Newswire) - Brooks Automation, Inc. (Nasdaq: BRKS) today reported financial results for the fiscal quarter ended Septemb |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 4, 2021 |
Brooks Automation Names Frank Casal to its Board of Directors Exhibit 99.1 Brooks Automation Names Frank Casal to its Board of Directors CHELMSFORD, Mass., November 3, 2021 (PR Newswire) ? Brooks Automation, Inc. (Nasdaq: BRKS) today announced that Frank Casal has been elected to its Board of Directors. Mr. Casal most recently served as Vice Chair, Audit for KPMG, LLP, the U.S. member firm of KPMG International (KPMGI). He joins the Brooks Board and Audit Co |
|
| October 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 7, 2021 |
? Exhibit 99.1 Brooks Automation Announces Transition and Departure Plans of Dr. Amy Liao ? CHELMSFORD, Mass., October 7, 2021 (PR Newswire) - Brooks Automation, Inc. (Nasdaq: BRKS) announced today that Dr. Amy Liao, President of Life Sciences Services, will be transitioning into the role of strategic advisor to the CEO until the end of this calendar year, at which time she will leave the Company |
|
| September 21, 2021 |
? Exhibit 99.1 BROOKS AUTOMATION ANNOUNCES AGREEMENT TO SELL ITS SEMICONDUCTOR SOLUTIONS GROUP BUSINESS TO THOMAS H. LEE PARTNERS ? Thomas H. Lee Partners to acquire the automation business for $3 billion in cash Transaction proceeds will be used to accelerate growth of life sciences business ? CHELMSFORD, Mass., September 20, 2021 (PRNEWSWIRE) - Brooks Automation, Inc. (Nasdaq: BRKS) today announ |
|
| September 21, 2021 |
Exhibit 99.2 Brooks Automation Conference Call: Divestiture of Brooks Semiconductor Solutions Group Business September 20, 2021 Exhibit 99.2 ? 2021 Brooks Automation, Inc. ? Proprietary Information Safe Harbor Statement ?Safe Harbor? Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Compa |
|
| September 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| September 21, 2021 |
Exhibit 2.1 EQUITY INTEREST PURCHASE AGREEMENT by and between BROOKS AUTOMATION, INC. and ALTAR BIDCO, INC. Dated as of September 20, 2021 ? ? ? ? ? ? ? ? TABLE OF CONTENTS ? ? ? ? ? Page ARTICLE I DEFINITIONS AND DOCUMENTARY CONVENTIONS 2 1.1 Definitions 2 1.2 Exhibits and Schedules; Interpretation 22 ARTICLE II PURCHASE AND SALE OF EQUITY INTERESTS 22 2.1 Sale and Purchase of Equity Interests 22 |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 5, 2021 |
Exhibit 99.1 Brooks Automation Reports Results of Third Quarter of Fiscal 2021, Ended June 30, 2021, and Announces Quarterly Cash Dividend ? Robust Demand and Strong Execution Drive Continued Growth in Revenue and Profitability ? CHELMSFORD, Mass., August 5, 2021 (PR Newswire) - Brooks Automation, Inc. (Nasdaq: BRKS) today reported financial results for the fiscal quarter ended June 30, 2021. ? ? |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 26, 2021 |
Conflict Minerals Report for the year ended December 31, 2020 Exhibit 1.01 Introduction ? ? Brooks Automation, Inc., also referred to as ?Brooks?, ?we?, ?our?, and ?us? is a leading provider of life science sample-based solutions and semiconductor manufacturing solutions worldwide. With over 40 years as a partner to the semiconductor manufacturing industry, Brooks is a provider of industry-leading precision vacuum robotics, integrated automation systems and |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ? BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware ? 0-25434 ? 04-3040660 (State or Other Jurisdiction of Incorporation) ? (Commission File Number) ? (IRS Employer Identification No.) ? 15 Elizabeth Drive, Chelmsford, MA ? 01824 (Address of Principal Exec |
|
| May 10, 2021 |
Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lindon G. Robertson, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Brooks Automation, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc |
|
| May 10, 2021 |
Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Brooks Automation, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc |
|
| May 10, 2021 |
Exhibit 99.2 ? BROOKS ANNOUNCES INTENTION TO SEPARATE INTO TWO INDEPENDENT PUBLICLY TRADED COMPANIES ? Separation Will Create Focused, High-Growth Life Sciences and Automation Companies Tax-Efficient Separation Expected to be Completed by End of Calendar Year 2021 ? CHELMSFORD, Mass., May 10, 2021 ? Brooks Automation, Inc. (?Brooks?) (Nasdaq: BRKS) today announced its intention to separate its bus |
|
| May 10, 2021 |
Exhibit 99.1 Brooks Automation Reports Results of Second Quarter of Fiscal 2021, Ended March 31, 2021, and Announces Quarterly Cash Dividend ? Record Revenue and Continued Margin Expansion in Both Life Sciences and Semiconductor Solutions ? CHELMSFORD, Mass., May 10, 2021 (PR Newswire) - Brooks Automation, Inc. (Nasdaq: BRKS) today reported financial results for the second fiscal quarter of 2021, |
|
| May 10, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. )* Brooks Automation Inc (Name of Issuer) Common Stock (Title of Class of Securities) 114340102 (CUSIP Number) 12/31/2020 (Date of Event Which |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Brooks Automation Inc. Title of Class of Securities: Common Stock CUSIP Number: 114340102 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| February 4, 2021 |
As filed with the Securities and Exchange Commission on February 4, 2021 Registration No. |
|
| February 3, 2021 |
Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lindon G. Robertson, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Brooks Automation, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc |
|
| February 3, 2021 |
Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Brooks Automation, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc |
|
| February 3, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Numbe |
|
| February 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 2, 2021 |
Exhibit 99.1 Brooks Automation Reports Results of First Quarter of Fiscal 2021, Ended December 31, 2020, and Announces Quarterly Cash Dividend Strong Revenue Growth and Margin Expansion Year Over Year In Both Life Sciences and Semiconductor Solutions CHELMSFORD, Mass., February 2, 2021 (PR Newswire) - Brooks Automation, Inc. (Nasdaq: BRKS) today reported financial results for the first fiscal quar |
|
| February 1, 2021 |
Exhibit 10.1 BROOKS AUTOMATION, INC. 2020 EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Brooks Automation, Inc. 2020 Equity Incentive Plan, have the following meanings: “Administrator” means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 28, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26,2021 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| December 15, 2020 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permi |
|
| December 10, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2020 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 10, 2020 |
Brooks Automation Mourns the Sudden Passing of Board Member Mr. A. Clinton Allen Exhibit 99.1 Brooks Automation Mourns the Sudden Passing of Board Member Mr. A. Clinton Allen CHELMSFORD, Mass., December 8, 2020 (PRNewswire) - Brooks Automation, Inc. (Nasdaq:BRKS) announced today with great sadness that Mr. A. Clinton Allen, Director, passed away unexpectedly on December 6, 2020. Mr. Allen served on Brooks’ Board of Directors since 2003. He was 76. “We are all saddened by the s |
|
| November 18, 2020 |
EXHIBIT 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this annual report on Form 10-K of Brooks Automation, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances |
|
| November 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-25434 |
|
| November 18, 2020 |
Consent of PricewaterhouseCoopers LLP Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-202005, 333-142873, 333-123242, 333-216312 and 333-221826) of Brooks Automation, Inc. of our report dated November 18, 2020, relating to the consolidated financial statements and the effectiveness of internal control over fi |
|
| November 18, 2020 |
EXHIBIT 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lindon G. Robertson, certify that: 1. I have reviewed this annual report on Form 10-K of Brooks Automation, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances |
|
| November 18, 2020 |
EXHIBIT 21.01 BROOKS AUTOMATION, INC. SUBSIDIARIES OF THE REGISTRANT Legal Entity Jurisdiction 4titude Ltd UK Brooks Automation (France) SAS France Brooks Automation (Germany) GmbH Germany Brooks Automation (Singapore) PTE Ltd Singapore Brooks Automation Taiwan Company Ltd Taiwan Brooks Automation (UK) Ltd UK Brooks Automation Asia Ltd Korea Brooks Automation Israel Ltd Israel Brooks Automation Ko |
|
| November 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 10, 2020 |
Exhibit 99.1 Brooks Automation Reports its Fourth Quarter and Year-End Results of Fiscal 2020, Ended September 30, 2020, and Announces Quarterly Cash Dividend Significant Earnings Growth Driven by Operating Margin Expansion and Double-Digit Revenue Growth in Both Life Sciences and Semiconductor Solutions CHELMSFORD, Mass., November 10, 2020 (PR Newswire) - Brooks Automation, Inc. (Nasdaq: BRKS) to |
|
| July 31, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 00 |
|
| July 31, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2020 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| July 31, 2020 |
Exhibit 99.1 Brooks Automation Reports Results of its Third Quarter of Fiscal 2020, Ended June 30, 2020, and Announces Quarterly Cash Dividend Continued Revenue Growth and Earnings Expansion on Solid Execution Across Both Segments CHELMSFORD, Mass., July 30, 2020 (PR Newswire) - Brooks Automation, Inc. (Nasdaq: BRKS) today reported financial results for the third fiscal quarter, ended June 30, 202 |
|
| May 27, 2020 |
Exhibit 1.01 Introduction Brooks Automation, Inc., also referred to as “Brooks”, “we”, “our”, and “us” is a leading provider of life science sample-based solutions and semiconductor manufacturing solutions worldwide. The Company's Life Sciences business provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical rese |
|
| May 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0‑25434 04‑3040660 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 15 Elizabeth Drive, Chelmsford, MA 01824 (Address of Principal Executive Offices) |
|
| May 1, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 0 |
|
| April 30, 2020 |
Exhibit 99.1 Brooks Automation Reports Results of its Second Quarter of Fiscal 2020, Ended March 31, 2020, and Announces Quarterly Cash Dividend Double-digit Revenue Growth in Both Segments Supports High Growth in EPS CHELMSFORD, Mass., April 30, 2020 (PR Newswire) - Brooks Automation, Inc. (Nasdaq: BRKS), today reported financial results for the second fiscal quarter, ended March 31, 2020. Financ |
|
| April 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2020 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| April 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2020 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| April 13, 2020 |
Exhibit 99.1 Brooks Automation Reports Preliminary Results for its Second Quarter of Fiscal 2020, Ended March 31, 2020 and Timing of its Second Quarter Conference Call and Webcast CHELMSFORD, Mass., April 13, 2020 (PR Newswire) - Brooks Automation, Inc. (Nasdaq: BRKS) today reported preliminary financial results for the second fiscal quarter of 2020, ended March 31, 2020. Second Quarter FY2020 Pre |
|
| April 7, 2020 |
Brooks Automation Names Erica McLaughlin to Its Board of Directors Exhibit 99.1 Brooks Automation Names Erica McLaughlin to Its Board of Directors CHELMSFORD, Mass., April 6, 2020 (PRNewswire) - Brooks Automation, Inc. (Nasdaq:BRKS) today announced that Erica McLaughlin has been elected to its Board of Directors. Ms. McLaughlin, Senior Vice President and CFO of Cabot Corporation, joins the board and the audit committee, bringing deep leadership experience as a gl |
|
| April 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2020 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 12, 2020 |
BRKS / Brooks Automation, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Brooks Automation Inc Title of Class of Securities: Common Stock CUSIP Number: 114340102 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| February 6, 2020 |
Exhibit 31.01 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Stephen S. Schwartz, certify that: 1. I have reviewed this quarterly report on Form 10‑Q of Brooks Automation, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc |
|
| February 6, 2020 |
Exhibit 99.1 Brooks Automation Reports Results of First Quarter of Fiscal 2020, Ended December 31, 2019, and Announces Quarterly Cash Dividend CHELMSFORD, Mass., February 6, 2020 (PR Newswire) - Brooks Automation, Inc. (Nasdaq: BRKS), a leader in automation solutions for the semiconductor manufacturing and life sciences industries, today reported financial results for the first fiscal quarter of 2 |
|
| February 6, 2020 |
Exhibit 31.02 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lindon G. Robertson, certify that: 1. I have reviewed this quarterly report on Form 10‑Q of Brooks Automation, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc |
|
| February 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2020 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: December 31, 2019 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Numbe |
|
| January 29, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2020 BROOKS AUTOMATION, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-25434 04-3040660 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 30, 2019 |
BRKS / Brooks Automation, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on December 30, 2019 Registration No. |
|
| December 30, 2019 |
Power of Attorney for Michael Rosenblatt. POWER OF ATTORNEY The undersigned constitutes and appoints Stephen S. Schwartz, Lindon G. Robertson and Jason W. Joseph, and each of them singly, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective |
